Functional polymorphisms in COMT and SLC6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy

European Journal of Neurology

Volumn 21, Issue 7, 2014, Pages 989-995

  Cargnin, S ^a   Viana, M ^b   Ghiotto, N ^b   Bianchi, M ^b   Sances, G ^b   Tassorelli, C ^b,c   Nappi, G ^b   Canonico, P L ^a   Genazzani, A A ^a   Terrazzino, S ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

COMT; Detoxification; Medication overuse headache; Polymorphisms; Relapse; SLC6A4

Indexed keywords

CATECHOL METHYLTRANSFERASE; GENOMIC DNA; SEROTONIN TRANSPORTER; TRIPTAN DERIVATIVE; COMT PROTEIN, HUMAN; SLC6A4 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; DETOXIFICATION; DNA EXTRACTION; DRUG INDUCED HEADACHE; ENZYME POLYMORPHISM; FEMALE; FOLLOW UP; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIMARY HEADACHE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT; TREATMENT WITHDRAWAL; VARIABLE NUMBER OF TANDEM REPEAT; CHEMICALLY INDUCED; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HEADACHE DISORDERS, SECONDARY; RECURRENT DISEASE;

ADULT; CATECHOL O-METHYLTRANSFERASE; GENETIC PREDISPOSITION TO DISEASE; HEADACHE DISORDERS, SECONDARY; HUMANS; POLYMORPHISM, GENETIC; PROGNOSIS; RECURRENCE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84902272381     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12424     Document Type: Article

References (22)

1. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004; 3: 475-483.
2. Katsarava Z, Mussig M, Dzagniza A, Frietsche G, Diener HC, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005; 25: 12-15.
3. Bøe MG, Salvesen R, Mygland A. Chronic daily headache with medication overuse: predictors of outcome 1 year after withdrawal therapy. Eur J Neurol 2009; 16: 705-712.
4. Sances G, Ghiotto N, Galli F, et al. Risk factors in medication-overuse headache: a 1-year follow-up study (CARE II protocol). Cephalalgia 2010; 30: 329-336.
5. Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004; 29: 1943-1961.
6. Andersen S, Skorpen F. Variation in the COMT gene: implications for pain perception and pain treatment. Pharmacogenomics 2009; 10: 669-684.
7. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003; 299: 1240-1243.
8. Schmahl C, Ludäscher P, Greffrath W, et al. COMT val158met polymorphism and neural pain processing. PLoS ONE 2012; 7: e23658.
9. Ferraro S, Grazzi L, Muffatti R, et al. In medication-overuse headache, fMRI shows long-lasting dysfunction in midbrain areas. Headache 2012; 52: 1520-1534.
10. Lesch KP, Mössner R. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry 1998; 44: 179-192.
11. Terrazzino S, Tassorelli C, Sances G, et al. Association of haplotype combination of serotonin transporter gene polymorphisms with monthly headache days in MOH patients. Eur J Neurol 2012; 19: 69-75.
12. Ghiotto N, Sances G, Galli F, et al. Medication overuse headache and applicability of the ICHD-II diagnostic criteria: 1-year follow-up study (CARE I protocol). Cephalalgia 2009; 29: 233-243.
13. Halleland H, Lundervold AJ, Halmoy A, Haavik J, Johansson S. Association between catechol O-methyltransferase (COMT) haplotypes and severity of hyperactivity symptoms in adults. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 403-410.
14. Cargnin S, Magnani F, Viana M, et al. An opposite-direction modulation of the COMT Val158Met polymorphism on the clinical response to intrathecal morphine and triptans. J Pain 2013; 14: 1097-1106.
15. Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006; 22: 1928-1929.
16. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edn (beta version). Cephalalgia 2013; 33: 629-808.
17. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 2010; 9: 391-401.
18. Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology 2003; 60: 1682-1683.
19. Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005; 14: 135-143.
20. Nackley AG, Shabalina SA, Tchivileva IE, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006; 314: 1930-1933.
21. Hagen K, Jensen R, Bøe MG, Stovner LJ. Medication overuse headache: a critical review of end points in recent follow-up studies. J Headache Pain 2010; 11: 373-377.
22. Jiang H, Xie T, Ramsden D, Ho SL. Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology 2003; 45: 1011-1118.